Protagonist Therapeutics (PTGX) versus Its Peers Critical Contrast

Protagonist Therapeutics (NASDAQ:PTGX) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare Protagonist Therapeutics to similar businesses based on the strength of its earnings, risk, analyst recommendations, dividends, profitability, institutional ownership and valuation.

Risk & Volatility

Protagonist Therapeutics has a beta of 1.21, suggesting that its stock price is 21% more volatile than the S&P 500. Comparatively, Protagonist Therapeutics’ rivals have a beta of -1.84, suggesting that their average stock price is 284% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings for Protagonist Therapeutics and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	0	0	16	1	3.06
Protagonist Therapeutics Competitors	9869	15280	45598	1598	2.54

Protagonist Therapeutics currently has a consensus target price of $166.67, suggesting a potential upside of 23.58%. As a group, “Biotechnology” companies have a potential upside of 121.32%. Given Protagonist Therapeutics’ rivals higher probable upside, analysts plainly believe Protagonist Therapeutics has less favorable growth aspects than its rivals.

Institutional and Insider Ownership

98.6% of Protagonist Therapeutics shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 5.2% of Protagonist Therapeutics shares are held by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Protagonist Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	62.04%	42.83%	40.29%
Protagonist Therapeutics Competitors	-12,323.33%	-195.38%	-30.39%

Valuation and Earnings

This table compares Protagonist Therapeutics and its rivals gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Protagonist Therapeutics	$46.02 million	-$130.15 million	28.57
Protagonist Therapeutics Competitors	$750.19 million	$13.49 million	-19.24

Protagonist Therapeutics’ rivals have higher revenue and earnings than Protagonist Therapeutics. Protagonist Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Summary

Protagonist Therapeutics beats its rivals on 9 of the 13 factors compared.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops peptide-based medicines, primarily for inflammatory and blood disorders. Its research approach uses engineered peptides designed to act on specific biological targets. The company’s programs include rusfertide, a hepcidin mimetic being developed for polycythemia vera, and icotrokinra, an oral interleukin-23 receptor antagonist being developed for immune-mediated diseases. Protagonist has entered into licensing and development collaborations for these programs with Takeda and Johnson & Johnson, respectively; they are investigational medicines, not approved treatments.